Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Maintains $111 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a $111 price target.
July 23, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Ultragenyx Pharmaceutical with a $111 price target.
The reaffirmation of a Buy rating and a specific price target of $111 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100